【一周新资讯--结直肠癌 229】2024 W4501

主要研究结果：

• 共纳入35例标准一线/二线治疗难治性mCRC，既往伊立替康且维持治疗期间进展的患者也可入组

• 31例可评估疗效，ORR(主要终点)为25.8%，DCR为93.5%

• 中位PFS为9.2个月，中位OS未达到，1年OS为73.5%

• 最常见的3/4级TRAE为中性粒细胞减少34.3%、贫血17.1%和血小板减少8.6%

参考文献：

Li B, Yang W, Liu N, Bi D, Yang T, Wu G, Sun Y. Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study. Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02885-3. Epub ahead of print. PMID: 39448860.

主要研究结果：

• 纳入观察等待随后局部再复发的cCR患者与TME后接近CR患者(508/893)

• 局部再复发组的远处转移率显著更高(22.8% vs. 10.2, P≤0.001)

• 远处转移的独立风险因素：局部再复发(vs. 再评估时TME, P=0.001)，手术时ypT3-4(P=0.016)和ypN+(P=0.001)

• 局部再复发组的3年无远处转移生存率显著更差(75% vs. 87%, P=0.001)

• 根据病理学分期分层时，所有期别中，再复发组显著更差(P≤0.009)

参考文献：

Fernandez LM, São Julião GP, Santacruz CC, Renehan AG, Cano-Valderrama O, Beets GL, Azevedo J, Lorente BF, Rancaño RS, Biondo S, Espin-Basany E, Vailati BB, Nilsson PJ, Martling A, Van De Velde CJH, Parvaiz A, Habr-Gama A, Perez RO; International Watch & Wait Database Consortium (IWWD) and the Spanish Rectal Cancer Viking Consortium (VIKINGO); International Watch & Wait Database Consortium (IWWD) & Spanish Rectal Cancer Viking Consortium. Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer. J Clin Oncol. 2024 Oct 28:JCO2400405. doi: 10.1200/JCO.24.00405. Epub ahead of print. PMID: 39467217.

主要研究结果：

• Onvansertib是一种Polo样激酶1(PLK1)抑制剂

• 共纳入53例既往接受过奥沙利铂/FU±贝伐珠单抗治疗的KRAS突变mCRC

• 接受onvansertib 15mg/m2 QD D1-15/15-19 Q28D与FOLFIRI+贝伐珠单抗(D1/15)

• 主要终点ORR为26.4%，中位DOR为11.7个月，3/4级AE为62%

• 事后分析：既往未接受过贝伐珠单抗者的ORR与PFS显著优于既往接受过贝伐珠单抗者

• ORR：76.9% vs. 10.0%, P<0.001

• 中位PFS：14.9 vs. 6.6个月, HR=0.16; P<0.001

参考文献：

Ahn DH, Ridinger M, Cannon TL, Mendelsohn L, Starr JS, Hubbard JM, Kasi A, Barzi A, Samuëlsz E, Karki A, Subramanian RA, Yemane D, Kim R, Wu CC, Croucher PJP, Smeal T, Kabbinavar FF, Lenz HJ. Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. J Clin Oncol. 2024 Oct 30:JCO2401266. doi: 10.1200/JCO-24-01266. Epub ahead of print. PMID: 39475591.